McCune J M, Namikawa R, Shih C C, Rabin L, Kaneshima H
HIV Group, SyStemix, Palo Alto, CA 94303.
Science. 1990 Feb 2;247(4942):564-6. doi: 10.1126/science.2300816.
The SCID-hu mouse, engrafted with human hematolymphoid organs, is permissive for infection with the human immunodeficiency virus (HIV). This mouse model was used to test compounds for antiviral efficacy. Two weeks after infection with HIV, 100 percent (40/40) of SCID-hu mice were positive for HIV by the polymerase chain reaction. When first treated with 3'-azido-3'-deoxythymidine (AZT), none (0/17) were HIV-positive by this assay. However, AZT-treated SCID-hu mice did have a few infected cells; after AZT treatment was stopped, viral spread was detected by polymerase chain reaction in such mice. Thus, the SCID-hu mouse provides a means to directly compare new antiviral compounds with AZT and to further improve antiviral efficacy.
植入人类血液淋巴器官的重症联合免疫缺陷-人类(SCID-hu)小鼠可被人类免疫缺陷病毒(HIV)感染。该小鼠模型用于测试化合物的抗病毒疗效。感染HIV两周后,通过聚合酶链反应检测,100%(40/40)的SCID-hu小鼠HIV呈阳性。首次用3'-叠氮-3'-脱氧胸苷(AZT)治疗时,通过该检测方法,无一(0/17)只小鼠HIV呈阳性。然而,经AZT治疗的SCID-hu小鼠确实有一些被感染的细胞;停止AZT治疗后,通过聚合酶链反应在这些小鼠中检测到病毒传播。因此,SCID-hu小鼠提供了一种直接将新的抗病毒化合物与AZT进行比较并进一步提高抗病毒疗效的方法。